lactoferrin and Sleep-Wake-Disorders

lactoferrin has been researched along with Sleep-Wake-Disorders* in 1 studies

Trials

1 trial(s) available for lactoferrin and Sleep-Wake-Disorders

Article	Year
Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance. Nutrients, 2017, Aug-18, Volume: 9, Issue:8 Hepatitis C virus infection and interferon treatment have shown to be risk factors for sleep disorder health-related quality of life.. To determine whether the effects of resveratrol on sleep disorders were associated with different tests in subjects with chronic hepatitis C treated with Peg-IFN-α and RBV.. In this prospective, randomized, placebo controlled, double blind clinical trial, 30 subjects (Group A) with chronic hepatitis received Pegylated-Interferon-α2b (1.5 mg/kg per week), Ribavirin and placebo (. The comparison between Group A and Group B showed significant differences after six months in C-reactive protein (. Supplementation with Resveratrol decreased General Health Questionnaire score and reduced sleep disorders in patients treated with Peg-IFN-α and RBV. Topics: Acetylcysteine; Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Blood Glucose; Body Mass Index; C-Reactive Protein; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lactoferrin; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Resveratrol; Ribavirin; Sleep Wake Disorders; Stilbenes; Surveys and Questionnaires	2017

Article

Year

Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance.

Nutrients, 2017, Aug-18, Volume: 9, Issue:8

Hepatitis C virus infection and interferon treatment have shown to be risk factors for sleep disorder health-related quality of life.. To determine whether the effects of resveratrol on sleep disorders were associated with different tests in subjects with chronic hepatitis C treated with Peg-IFN-α and RBV.. In this prospective, randomized, placebo controlled, double blind clinical trial, 30 subjects (Group A) with chronic hepatitis received Pegylated-Interferon-α2b (1.5 mg/kg per week), Ribavirin and placebo (. The comparison between Group A and Group B showed significant differences after six months in C-reactive protein (. Supplementation with Resveratrol decreased General Health Questionnaire score and reduced sleep disorders in patients treated with Peg-IFN-α and RBV.

Topics: Acetylcysteine; Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Blood Glucose; Body Mass Index; C-Reactive Protein; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lactoferrin; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Resveratrol; Ribavirin; Sleep Wake Disorders; Stilbenes; Surveys and Questionnaires

2017